Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea
Gabriel Tremblay,1 Unnati Majethia,2 Janis L Breeze,3 Ilias Kontoudis,4 Jeongae Park5 1Geneconomics Inc., Lévis, Quebec, Canada; 2Global Value and Access, Eisai Inc., Woodcliff Lake, NJ, 3Tufts Clinical and Translational Science Institute, Tufts University, and Institute for Clinical Research and He...
Saved in:
Main Authors: | Tremblay G (Author), Majethia U (Author), Breeze JL (Author), Kontoudis I (Author), Park J (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2016-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Budget impact of eribulin in metastatic breast cancer in Russian Federation
by: S. K. Zyryanov, et al.
Published: (2018) -
Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy
by: Doherty MK, et al.
Published: (2015) -
Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy [Corrigendum]
by: Doherty MK, et al.
Published: (2015) -
Prognostic significance of neutrophil to lymphocyte ratio in patients with metastatic breast cancer on the background of eribulin therapy
by: A. V. Zyuzyukina, et al.
Published: (2022) -
Microenvironment-related predictive markers of the therapeutic effectiveness of eribulin in patients with locally advanced or metastatic breast cancer: pilot study
by: L. A. Tashireva, et al.
Published: (2022)